

# A group treatment for antenatal anxiety

<b>Submission date</b> 21/09/2023	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/02/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 03/12/2025	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Up to a quarter of women struggle with serious anxiety symptoms during pregnancy. Many women will not improve without treatment, with symptoms continuing postnatally and for some, leading to depression. High anxiety during pregnancy is related to negative outcomes in childbirth and baby development. Babies of mothers who struggle with anxiety during pregnancy can have more problems with their emotions, behaviours and cognitive development. If the mother's anxiety continues after the baby is born it can make it difficult for the mother to bond with the baby and provide the kind of care the baby needs. Together, the impact of untreated perinatal mental health problems cost over £8 billion each year in England. Despite the fact that anxiety problems are more common during pregnancy and have many negative effects, there is a lack of high quality research about the best way to help mothers. In the NHS most mothers with antenatal anxiety (65%) are seen in primary mental health care (IAPT), but IAPT lacks treatments that specifically address antenatal anxiety.

We will test whether CALM 1) improves anxiety in pregnant women during pregnancy; 2) has sustained benefits in the postnatal period, up to a year after the baby is born; 3) improves the relationship the parent has with the child and how the child develops and 4) is cost-effective for the NHS to deliver. We will also interview parents who completed CALM to see which parts helped them the most, and we will ask care providers about the best ways to ensure CALM fits within the NHS.

### Who can participate?

Any woman or birthing person over the age of 18 who scores 8 and above on the GAD-7.

### What does the study involve?

Eligible participants will be randomised to either receive the intervention and treatment as usual or solely treatment as usual. Those in the intervention will receive a 4-session group based online intervention delivered by healthcare and psychological practitioners. The intervention includes partners or a close support and the group encourages peer support. All participants will be asked to complete questionnaires at 6 timepoints (at the start, 22 and 32 weeks pregnant, 2/6 /12 months post birth).

### What are the possible benefits and risks of participating?

There is a lack of information about the effectiveness and long-term benefits of a group

treatment for antenatal anxiety compared to usual care. Regardless of the group you will be randomised into, your input in the clinical trial will contribute to the evidence around what treatment is effective in targeting pregnancy-related anxiety. If you do decide to take part, as a thank you gesture we will offer you a voucher.

We do not expect there are any disadvantages or risks to you. All the sessions will be arranged at a time to suit you and your partner. You may feel anxious before or tired after taking part in the sessions or while completing the questionnaires, but we will do everything we can to minimise or prevent this.

Where is the study run from?

The Universities of Exeter, Manchester, Cambridge, and Birmingham are leading the recruitment. This trial also has academics from Imperial College London, University of Bath, Anna Freud Centre and Kings College London. It is sponsored by Devon Partnership NHS Trust.

When is the study starting and how long is it expected to run for?

September 2023 to August 2027

Who is funding the study?

National Institute of Health Research - Health Technology Assessment Programme (UK)

Who is the main contact?

Dr Antoinette Davey, antoinette.davey@exeter.ac.uk

## Contact information

**Type(s)**

Public

**Contact name**

Dr Antoinette Davey

**ORCID ID**

<https://orcid.org/0000-0002-5118-6912>

**Contact details**

Devon Partnership Trust

Wonford House

Dryden Road

Exeter

United Kingdom

EX2 5AF

+44 (0)7828843266

antoinette.davey@exeter.ac.uk

**Type(s)**

Principal investigator

**Contact name**

Prof Heather O'Mahen

**ORCID ID**

<https://orcid.org/0000-0003-3458-430X>

**Contact details**

University of Exeter  
Faculty of Health and Life Sciences  
Psychology Department  
Washington Singer Labs  
Perry Road  
Exeter  
United Kingdom  
EX44QG  
+44 (0)1392724651  
H.OMahen@exeter.ac.uk

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

333463

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

29369, IRAS 333463, CPMS 60522

**Study information****Scientific Title**

ACORN-II: A multi-site randomised COntrolled trial to evaluate the impact of a group tReatment for aNtenatal anxiety

**Acronym**

ACORN-II

**Study objectives**

The primary objective is to test whether CALM + Treatment as usual (TAU) reduces anxiety in pregnant women relative to TAU alone. We will also assess whether CALM + TAU has sustained benefits up to a year after the baby is born compared to TAU alone.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 24/01/2024, South West - Cornwall & Plymouth Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8143; cornwallandplymouth.rec@hra.nhs.uk), ref: 24/SW/0013

## **Study design**

Group sequential multi-centre parallel arm individually randomized controlled trial with internal pilot interim monitoring for futility and economic and process evaluation

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Antenatal anxiety

## **Interventions**

Potential participants will be screened for anxiety at first-trimester scanning clinics. If individuals score 8 and above on the GAD-7, they will be eligible for the trial.

Eligible participants who consent will be randomly allocated on a 1:1 basis to CALM + TAU or TAU only using permuted block randomisation which will be stratified by site and anxiety diagnosis pre-pregnancy versus de novo antenatal anxiety. Randomisation will be delivered by a web-based randomisation system (integrated within the trial REDCap system).

The CALM intervention comprises four 2-hour online group sessions delivered to both the pregnant woman/birthing person and their partner and one 2-hour postnatal reunion. It is delivered by a healthcare and psychological practitioner. The intervention focuses on strategies that: (1) reduce avoidance associated with worry, (2) improve the ability to tolerate uncertainty that contributes to anxious worry in the perinatal period and (3) improve relationship satisfaction through joint communication skills about how to manage worry together.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Anxiety will be measured using the Generalised Anxiety Disorder -7 PROM at baseline, 22 & 32 weeks pregnant, and postnatally at 3, 6, and 12 months.

## **Key secondary outcome(s)**

1. Antenatal anxiety measured using Pregnancy-Related Anxiety Questionnaire – Revised 2 (PRAQ-R2) at baseline, 22 weeks and 32 weeks
2. Depression using Patient Health Questionnaire-9 (PHQ-9) at baseline, 22 & 32 weeks pregnant, and postnatally at 3, 6, and 12 months.
3. Relationship adjustment measured using Revised Dyadic Adjustment Scale (DAS) at baseline, 22 and 32 weeks pregnant.
4. Health related quality of life measured using EuroQol-5 Dimensions-5 Level (EQ-5D-5L) at baseline, 22 & 32 weeks pregnant, and postnatally at 3, 6, and 12 months.
5. Service use measured using Adult Service Use Schedule (AD-SUS) at baseline, 32 weeks pregnant and 12 months postnatal.
6. Infant behaviour and temperament measured using Infant Behavior Questionnaire – Revised (IBQ-R) at 6 months postnatal.
7. Perceptions of childbirth measured using Maternal Perceptions of Support and Control in

Birth (SCIB) at 3 months postnatal.

8. Parent and infant interaction measured using 10-minute videoed interaction and coded using the well-validated NICHD parent-infant sensitivity, intrusiveness scales at 12 months postnatal.

9. Social, emotional and behavioural problems in the infant measured using Brief Infant Toddler Social and Emotional Assessment (BITSEA) at 12 months postnatal.

10. Child development measured using Ages and Stages 3rd edition at 12 months postnatal.

**Completion date**

31/08/2027

## Eligibility

**Key inclusion criteria**

Pregnant women and birthing persons aged 18+ years who score above clinical threshold (8 or more) (on a standard anxiety screening measure (GAD-7))

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

Female

**Total final enrolment**

0

**Key exclusion criteria**

1. Actively suicidal
2. Substance abuse
3. Psychosis
4. Have childbirth-related PTSD (i.e., individuals eligible to receive PTSD treatment in maternal mental health services)
5. Receiving current psychological treatment for anxiety at baseline interview

**Date of first enrolment**

01/05/2024

**Date of final enrolment**

31/03/2026

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

### **Royal Devon University Healthcare NHS Foundation Trust**

Royal Devon University NHS Ft

Barrack Road

Exeter

England

EX2 5DW

## Study participating centre

### **St Mary's Hospital**

Hathersage Rd

Manchester

England

M13 0JH

## Study participating centre

### **Royal London Hospital and Associated Community Services NHS Trust**

The Royal London Hospital

Whitechapel

London

England

E1 1BB

## Study participating centre

### **Homerton Hospital**

Homerton Row

London

England

E9 6SR

## Study participating centre

### **Birmingham Women's NHS Foundation Trust**

Birmingham Womens Hospital

Metchley Park Road  
Birmingham  
England  
B15 2TG

## Sponsor information

### Organisation

Devon Partnership NHS Trust

### ROR

<https://ror.org/04fkxrb51>

## Funder(s)

### Funder type

Government

### Funder Name

Health Technology Assessment Programme

### Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

<b>Output type</b>	<b>Details</b>	<b>Date created</b>	<b>Date added</b>	<b>Peer reviewed?</b>	<b>Patient-facing?</b>
<a href="#">Participant information sheet</a>	version 1	04/12/2023	29/01/2024	No	Yes
<a href="#">Participant information sheet</a>	version 1.0	07/11/2023	29/01/2024	No	Yes